MONOCLONAL ANTIBODIES DEFINE CARCINOMA ASSOCIATED AND DIFFERENTIATION ANTIGENS

这些研究涉及到克隆的产生和利用。 用于识别和表征人类癌症相关的抗体(MAb) 乳腺和结肠上皮的抗原和分化抗原。 这些单抗被用来更好地了解细胞生物学和 人类癌症的发病机制，并提供试剂用于 人类癌症管理的几个方面。这些措施包括： 隐匿性肿瘤细胞的检测；进一步定义 “正常”、发育不良和癌细胞群体的分化； 血清抗原分析；原发和转移瘤的放射定位 使用放射性标记的原位癌损害(和潜在的治疗) 单抗免疫球蛋白和碎片。这些研究分为 调查的四个领域：(1)产生和表征一个 定义一种新的肿瘤相关抗原(TAG-72)的单抗； 用于表位分析的单抗的研制和鉴定 差异表达的癌胚抗原(CEA) 癌细胞群体；(Iii)细胞的产生和特征 单抗与转移细胞群相关的蛋白质，以及(Iv) 乳腺和结肠分化的定义和特征 抗原。

These studies involve the generation and utilization of monoclonal antibodies (MAbs) to identify and characterize human carcinoma associated antigens and differentiation antigens of mammary and colonic epithelium. These MAbs are being used to better understand the cell biology and pathogenesis of human carcinomas, and to provide reagents for use in several aspects of the management of human carcinomas. These include: detection of occult tumor cells; further defining the degree of differentiation of "normal", dysplastic, and carcinoma cell populations; serum antigens assays; and radiolocalization of primary and metastatic carcinoma lesions in situ (and potentially therapy) using radiolabeled monoclonal immunoglobulins and fragments. These studies are divided into four areas of investigation: (I) The generation and characterization of an MAb that defines a novel tumor associated antigen (TAG-72); (II) The development and characterization of MAbs to a repertoire of epitopes on carcinoembryonic antigen (CEA) which are differentially expressed among carcinoma cell populations; (III) The generation and characterization of MAbs to proteins associated with metastatic cell populations, and (IV) The definition and characterization of breast and colon differentiation antigens.